Cytokinetics, Incorporated Company Profile (NASDAQ:CYTK)

About Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics, Incorporated logoCytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYTK
  • CUSIP: N/A
  • Web:
  • Market Cap: $674.18 million
  • Outstanding Shares: 45,083,000
Average Prices:
  • 50 Day Moving Avg: $13.64
  • 200 Day Moving Avg: $12.85
  • 52 Week Range: $8.51 - $17.20
  • Trailing P/E Ratio: 195.95
  • Foreward P/E Ratio: -6.94
  • P/E Growth: -0.39
Sales & Book Value:
  • Annual Revenue: $102.14 million
  • Price / Sales: 6.40
  • Book Value: $2.20 per share
  • Price / Book: 6.59
  • EBIDTA: $3.88 million
  • Net Margins: 1.53%
  • Return on Equity: 1.94%
  • Return on Assets: 0.90%
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 5.74%
  • Quick Ratio: 5.74%
  • Average Volume: 769,292 shs.
  • Beta: 1.97
  • Short Ratio: 5.8
Frequently Asked Questions for Cytokinetics, Incorporated (NASDAQ:CYTK)

What is Cytokinetics, Incorporated's stock symbol?

Cytokinetics, Incorporated trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics, Incorporated's earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings results on Thursday, February, 16th. The company reported $0.16 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.55. The business earned $33.14 million during the quarter, compared to analyst estimates of $14.10 million. Cytokinetics, Incorporated had a net margin of 1.53% and a return on equity of 1.94%. View Cytokinetics, Incorporated's Earnings History.

Where is Cytokinetics, Incorporated's stock going? Where will Cytokinetics, Incorporated's stock price be in 2017?

9 analysts have issued 1 year price targets for Cytokinetics, Incorporated's stock. Their forecasts range from $15.00 to $25.00. On average, they anticipate Cytokinetics, Incorporated's stock price to reach $21.11 in the next twelve months. View Analyst Ratings for Cytokinetics, Incorporated.

What are analysts saying about Cytokinetics, Incorporated stock?

Here are some recent quotes from research analysts about Cytokinetics, Incorporated stock:

  • 1. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (7/17/2017)
  • 2. Rodman & Renshaw analysts commented, "Our price target is based on our clinical net present value (NPV) model, which is currently driven by omecamtiv mecarbil ($19.77/share) and modest contributions from tirasemtiv ($4.26/share) and CK-107 ($1.05/share). We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/23/2017)
  • 3. HC Wainwright analysts commented, "We have adjusted our 2017 estimates downward accordingly. The company had a net loss of $4.3M in 4Q16, or ($0.81) per share based on shares adjusted for the 1-for-10 reverse split effective on February 27. 2016. The loss was lower than our estimate of $4.9M due to improved expense management. For the fiscal year 2016, TearLab had $28M in revenue, representing 11% growth over that of 2015, and $19.9M in net loss. In our view, the softened growth rate in the Flex program and in international markets could continue in 2017. Therefore, we currently project a conservative low single-digit growth in revenue in 2017. Our valuation of the company has decreased from $140M to $105M. Excluding debt, our estimated market value of the firm is $79M. Assuming 6.5M shares outstanding at the end of 2017, we project a 12-month price target of $12 per share. Our previous price target was $2 before the reverse split. Importantly, TearLab has begun a process to explore strategic alternatives, which does not preclude a sale of the company." (3/13/2017)
  • 4. Cantor Fitzgerald analysts commented, "We rate CYTK Overweight and maintain our $21 price target. Cytokinetics has three late-stage programs with quality partners that should begin to read data out in the next year. The company is targeting substantial unmet medical needs and has been methodically pursuing clinical development for its candidates. We think the major overhangs have receded from the shares and that, with near-term data on the horizon, the shares have opportunity for valuation expansion." (2/17/2017)
  • 5. FBR & Co analysts commented, "On February 16, CYTK announced 4Q16 results dominated by the achievement of significant milestones in its cardiac muscle-directed clinical program (omecamtiv mecarbil, or OM) and important milestones in its skeletal muscle program (tirasemtiv and CK-2127107), which we think will continue to emerge in value in 2017. One highlight was the initiation of the GALACTIC-HF Phase III outcomes trial with OM by its partner Amgen. Another 4Q highlight was enrollment of the first patient in the open-label VIGOR-ALS trial with tirasemtiv, designed to assess the safety of tirasemtiv, which would be directed for long-term daily use in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). We think CYTK's valuation is disconnected from the value of the more than $1B in milestone payments that CYTK could realize from its partners. Therefore, we reiterate our Outperform rating." (2/17/2017)

Who are some of Cytokinetics, Incorporated's key competitors?

Who are Cytokinetics, Incorporated's key executives?

Cytokinetics, Incorporated's management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Independent Chairman of the Board
  • Robert I. Blum, President, Chief Executive Officer, Director
  • Ching Jaw, Chief Financial Officer, Senior Vice President
  • Sharon A. Barbari, Executive Vice President - Finance
  • Fady I. Malik M.D. Ph.D., Executive Vice President - Research and Development
  • Peter S. Roddy, Senior Vice President, Chief Accounting Officer
  • David W. Cragg, Senior Vice President - Human Resources
  • Bonnie A. Charpentier Ph.D., Senior Vice President - Regulatory Affairs and Compliance
  • Bradley Paul Morgan Ph.D., Senior Vice President - Research and Non-Clinical Development
  • Elisabeth Schnieders Ph.D., Senior Vice President - Business Development

Who owns Cytokinetics, Incorporated stock?

Cytokinetics, Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (6.40%), Fox Run Management L.L.C. (0.08%), Bank of Montreal Can (0.05%), Capstone Asset Management Co. (0.04%), Louisiana State Employees Retirement System (0.04%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Cytokinetics, Incorporated stock include Fady Ibraham Malik, L Patrick Gage and Robert I Blum. View Institutional Ownership Trends for Cytokinetics, Incorporated.

Who bought Cytokinetics, Incorporated stock? Who is buying Cytokinetics, Incorporated stock?

Cytokinetics, Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Capstone Asset Management Co., Louisiana State Employees Retirement System, Bank of Montreal Can and State of Alaska Department of Revenue. View Insider Buying and Selling for Cytokinetics, Incorporated.

How do I buy Cytokinetics, Incorporated stock?

Shares of Cytokinetics, Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics, Incorporated's stock price today?

One share of Cytokinetics, Incorporated stock can currently be purchased for approximately $14.50.

MarketBeat Community Rating for Cytokinetics, Incorporated (NASDAQ CYTK)
Community Ranking:  4.0 out of 5 (   )
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics, Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cytokinetics, Incorporated (NASDAQ:CYTK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.11)
Consensus Price Target: $21.11 (45.59% upside)

Analysts' Ratings History for Cytokinetics, Incorporated (NASDAQ:CYTK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Cantor FitzgeraldReiterated RatingOverweightMediumView Rating Details
4/29/2017Cowen and CompanyReiterated RatingOutperform$17.00 -> $19.00LowView Rating Details
4/25/2017HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
3/23/2017Rodman & RenshawReiterated RatingBuy$25.00MediumView Rating Details
2/17/2017FBR & CoReiterated RatingOutperform$24.00N/AView Rating Details
2/17/2017Needham & Company LLCReiterated RatingStrong-Buy$22.00N/AView Rating Details
2/17/2017Piper Jaffray CompaniesReiterated RatingOverweight$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$22.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$16.00 -> $14.00N/AView Rating Details
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Cytokinetics, Incorporated (NASDAQ:CYTK)
Earnings by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Earnings History by Quarter for Cytokinetics, Incorporated (NASDAQ CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2017Q416($0.39)$0.16$14.10 million$33.14 millionViewListenView Earnings Details
10/27/2016Q3($0.27)$0.74$6.67 million$59.05 millionViewListenView Earnings Details
7/28/2016Q2($0.28)($0.29)$7.80 million$5.80 millionViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)$8.14 million$8.42 millionViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
7/29/2015Q2($0.28)($0.27)$4.00 million$6.54 millionViewListenView Earnings Details
4/30/2015Q1($0.08)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)$6.50 million$9.42 millionViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytokinetics, Incorporated (NASDAQ:CYTK)
2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.66)($0.66)($0.66)
Q3 20171($0.70)($0.70)($0.70)
Q4 20171($0.75)($0.75)($0.75)
(Data provided by Zacks Investment Research)


Dividend History for Cytokinetics, Incorporated (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cytokinetics, Incorporated (NASDAQ:CYTK)
Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 58.58%
Insider Trades by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Institutional Ownership by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Insider Trades by Quarter for Cytokinetics, Incorporated (NASDAQ:CYTK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017Robert I BlumCEOSell5,000$12.14$60,700.00View SEC Filing  
6/1/2017Robert I BlumCEOSell5,000$13.62$68,100.00View SEC Filing  
12/29/2016Fady Ibraham MalikEVPSell5,633$12.36$69,623.88View SEC Filing  
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cytokinetics, Incorporated (NASDAQ:CYTK)
Latest Headlines for Cytokinetics, Incorporated (NASDAQ:CYTK)
DateHeadline logoCytokinetics, Incorporated (NASDAQ:CYTK) Downgraded by Zacks Investment Research - July 17 at 8:26 PM logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : July 17, 2017 - July 17 at 6:37 PM logoCytokinetics, Incorporated (NASDAQ:CYTK) Upgraded by BidaskClub to "Hold" - July 16 at 3:22 PM logoCytokinetics, Incorporated (CYTK) Upgraded at Zacks Investment Research - July 11 at 9:04 PM logoETFs with exposure to Cytokinetics, Inc. : July 11, 2017 - July 11 at 6:53 PM logoCytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Buy" from Analysts - July 11 at 2:12 PM logoCytokinetics presents baseline data on trial of CK-2127107 - Seeking Alpha - July 6 at 3:16 PM logoApplying 'Base And Swing' To Cytokinetics - Seeking Alpha - July 6 at 3:16 PM logoCytokinetics (CYTK) Reports Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer - July 6 at 3:04 AM logoCytokinetics, Incorporated (NASDAQ:CYTK) Expected to Announce Earnings of -$0.66 Per Share - July 6 at 12:30 AM logoRobert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - July 5 at 10:45 PM logoCytokinetics (CYTK) Reports Start of Phase 1b Clinical Trial of CK-2127107 - July 1 at 5:23 PM logoCytokinetics (CYTK) Reports Start of Phase 1b Clinical Trial of CK-2127107 - - June 30 at 12:07 AM logoCytokinetics begins Phase 1b clinical trial of CK-2127107 in elderly subjects with limited mobility - June 29 at 7:05 PM logoCytokinetics Announces Start of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility - June 29 at 7:05 PM logoDaily Technical Summary Reports on Biotech Stocks -- Concordia, Cytokinetics, Dermira, and Endocyte - June 27 at 4:54 PM logoCytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : June 27, 2017 - June 27 at 4:54 PM logoCytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA Conference - GlobeNewswire (press release) - June 25 at 2:59 AM logoCytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA Conference - June 23 at 5:16 PM logoCytokinetics, Incorporated (CYTK) Given Consensus Recommendation of "Buy" by Analysts - June 16 at 12:50 PM logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : June 15, 2017 - June 15 at 6:33 PM logoETFs with exposure to Cytokinetics, Inc. : June 12, 2017 - June 12 at 5:37 PM logoCytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $5.28 Million - June 11 at 7:44 AM logoZacks: Analysts Expect Cytokinetics, Inc. (CYTK) Will Post Earnings of -$0.66 Per Share - June 10 at 12:26 AM logoCytokinetics, Inc. :CYTK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 - June 9 at 5:03 PM logoCytokinetics, Inc. (CYTK) Upgraded by ValuEngine to "Hold" - June 4 at 9:16 PM logoInsider Selling: Cytokinetics, Inc. (CYTK) CEO Sells 5,000 Shares of Stock - June 2 at 8:42 PM logoCytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : June 2, 2017 - June 2 at 6:08 PM logoCytokinetics, Inc. (CYTK) Earns "Overweight" Rating from Cantor Fitzgerald - May 23 at 7:12 AM logoCytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages - May 22 at 12:24 PM logo Analysts Expect Cytokinetics, Inc. (CYTK) to Post -$0.68 EPS - May 15 at 2:22 PM logoCytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy - May 15 at 11:54 AM logoShort Interest in Cytokinetics, Inc. (CYTK) Increases By 74.3% - May 11 at 8:36 AM logoCytokinetics Announces Proposed Public Offering of Common Stock - May 9 at 5:25 AM logoCytokinetics Announces Pricing of Public Offering of Common Stock - May 9 at 5:25 AM logoCytokinetics, Inc. (CYTK) Cut to "Strong Sell" at Zacks Investment Research - May 4 at 9:49 PM logoCytokinetics (CYTK) Earns News Sentiment Rating of -0.19 - May 4 at 10:43 AM logoCytokinetics, Inc. (CYTK) to Post Q2 2017 Earnings of ($0.66) Per Share, FBR & Co Forecasts - May 4 at 9:19 AM logoCytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS - May 3 at 4:34 PM logoCytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS - May 3 at 4:34 PM logoCytokinetics (CYTK) Given Daily News Impact Score of 0.05 - May 1 at 6:30 PM logoCytokinetics Announces Results from Dose Escalation Phase of COSMIC-HF Presented at Heart Failure 2017 - May 1 at 8:13 AM logoFBR & Co Comments on Cytokinetics, Inc.'s Q1 2017 Earnings (CYTK) - May 1 at 7:09 AM logoCytokinetics' (CYTK) "Outperform" Rating Reiterated at Cowen and Company - April 29 at 8:02 PM logoSomewhat Favorable News Coverage Likely to Affect Cytokinetics (CYTK) Share Price - April 28 at 11:36 PM logoEdited Transcript of CYTK earnings conference call or presentation 27-Apr-17 8:30pm GMT - April 28 at 5:41 PM logoCytokinetics reports 1Q loss - April 28 at 5:41 PM logoCytokinetics, Inc. Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - April 27 at 5:10 PM logoCytokinetics, Inc. Reports First Quarter 2017 Financial Results - April 27 at 5:10 PM logoSomewhat Favorable Media Coverage Likely to Impact Cytokinetics (CYTK) Stock Price - April 25 at 7:28 PM



Cytokinetics, Incorporated (CYTK) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff